Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

BIZARRE: Reata pharmaceuticals s return on invested capital insights - You Need To See This

Benzinga Pro data, Reata Pharmaceuticals (NASDAQ:RETA) reported Q4 sales of $934.00 thousand. Earnings fell to a loss of $85.39 million, resulting in a 18.84% decrease from last quarter. Reata Pharmaceuticals collected $7.39 million in revenue during Q3, but reported earnings showed a $71.85 million loss.

Why Is ROIC Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.